Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000700730
Ethics application status
Approved
Date submitted
4/06/2013
Date registered
26/06/2013
Date last updated
7/07/2016
Type of registration
Prospectively registered

Titles & IDs
Public title
Vitamin D for correcting deficiency in adolescents: a general
practice-based randomised controlled trial
Scientific title
Vitamin D deficient adolescents randomised to 50000 international units (IU) of vitamin D3 given orally monthly or 150000 IU of vitamin D3 given orally 3-monthly or placebo given monthly and 3-monthly, assessed by correcting vitamin D deficiency, feasibility of recruiting adolescents using general practice, and obtaining pilot bone density outcome data.
Secondary ID [1] 282617 0
Nil
Universal Trial Number (UTN)
Trial acronym
GP VitD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Vitamin D deficiency 289308 0
Condition category
Condition code
Musculoskeletal 289645 289645 0 0
Osteoporosis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
50000 IU vitamin D3 orally monthly or 150000 IU (3 x 50 000 IU tablets) orally 3-monthly for 12 months
Intervention code [1] 287283 0
Treatment: Drugs
Comparator / control treatment
Placebo (tablet) orally monthly and 3-monthly. The placebo consists of a filler called microcrystalline cellulose (C6H10O5)n.
Control group
Placebo

Outcomes
Primary outcome [1] 289726 0
Correction of vitamin D deficiency which will be assessed by blood test measuring serum 25-hydroxyvitamin D
Timepoint [1] 289726 0
3, 6, and 12 months from commencement of treatment
Secondary outcome [1] 303111 0
Feasibility of using general practice as the setting through which vitamin D deficient adolescents can be identified and treated. This will be assessed by assessing how long it takes to recruit 33 adolescents and keeping track of the number of adolescents contacted, screened and then enrolled in the study.


Timepoint [1] 303111 0
Recruitment and screening
Secondary outcome [2] 303112 0
Obtaining pilot bone density outcome data by measuring bone mineral density (BMD) at the total hip, lumbar spine and femoral neck determined using dual-energy x-ray absorptiometry.
Timepoint [2] 303112 0
12 months from commencement of treatment

Eligibility
Key inclusion criteria
Healthy adolescents aged 15-17 years.

Mild to moderate vitamin D deficiency (serum 25-OHD 12.5-50 nmol/L).

No known severe renal impairment, malabsorption, pregnancy, or lactation.

No clinical signs of rickets.

No reason known to GP to prevent participation or which makes making contact with the young person inappropriate (there may be cases where for reasons of patient confidentiality the GP will not wish a letter to be sent to a young person’s parents for example).
Minimum age
15 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Normal vitamin D levels (serum 25-OHD > 50 nmol/L).

Severe vitamin D deficiency (serum 25-OHD < 12.5 nmol/L). These patients will be referred to their GP for assessment and consideration of treatment. We will send a copy of these results together with a letter outlining appropriate treatment advice to the GP.

Known severe renal impairment, malabsorption, pregnancy, or lactation.

Clinical signs of rickets.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis
Based on our previous pilot study, we expect near total correction of mild to moderate vitamin D deficiency by a dose equivalent of 300,000IU orally of vitamin D3 over 6 months and that only 16% of children receiving placebo would correct their vitamin deficiency. Assuming 10% drop out (i.e. 10 children remaining in each group at 12 months) and with statistical significance set at p<0.05 (two-tailed), we have power of 0.85 to detect a difference in prevalence of deficiency between each vitamin D supplemented group and placebo of 70% i.e. between 90% of children no longer being deficient in vitamin D groups and 20% of children no longer being deficiency in the placebo group.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/07/2013
Actual
14/10/2013
Date of last participant enrolment
Anticipated
Actual
8/04/2015
Date of last data collection
Anticipated
6/04/2016
Actual
6/04/2016
Sample size
Target
33
Accrual to date
Final
28
Recruitment in Australia
Recruitment state(s)
TAS

Funding & Sponsors
Funding source category [1] 287395 0
Charities/Societies/Foundations
Name [1] 287395 0
The Royal Australian College of General Practitioners
Country [1] 287395 0
Australia
Primary sponsor type
University
Name
Menzies Research Institute Tasmania, University of Tasmania
Address
17 Liverpool St (Private Bag 23)
Hobart, TAS
7000
Country
Australia
Secondary sponsor category [1] 286136 0
None
Name [1] 286136 0
Address [1] 286136 0
Country [1] 286136 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 289372 0
Tasmania Health & Medical Human Research Ethics Committee (EC00337)
Ethics committee address [1] 289372 0
Ethics committee country [1] 289372 0
Australia
Date submitted for ethics approval [1] 289372 0
10/12/2012
Approval date [1] 289372 0
28/05/2013
Ethics approval number [1] 289372 0
H0012969

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 40518 0
A/Prof Tania Winzenberg
Address 40518 0
Menzies Research Institute Tasmania
17 Liverpool St (Private Bag 23)
Hobart, TAS
7000
Country 40518 0
Australia
Phone 40518 0
+61 3 6226 7770
Fax 40518 0
Email 40518 0
Tania.Winzenberg@utas.edu.au
Contact person for public queries
Name 40519 0
Tania Winzenberg
Address 40519 0
Menzies Research Institute Tasmania
17 Liverpool St (Private Bag 23)
Hobart, TAS
7000
Country 40519 0
Australia
Phone 40519 0
+61 3 6226 7770
Fax 40519 0
Email 40519 0
Tania.Winzenberg@utas.edu.au
Contact person for scientific queries
Name 40520 0
Tania Winzenberg
Address 40520 0
Menzies Research Institute Tasmania
17 Liverpool St (Private Bag 23)
Hobart, TAS
7000
Country 40520 0
Australia
Phone 40520 0
+61 3 6226 7770
Fax 40520 0
Email 40520 0
Tania.Winzenberg@utas.edu.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.